Genmab stock enters new phase after three cancer-drug wins

Published on 11/04/2026 at 04:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock enters a new phase after three positive cancer-drug trials in October. Third-quarter results are due on November 5.

Genmab enters a new growth phase

Three positive Phase 3 trial results in October strengthened Genmab's pipeline outlook.
The company is using royalty income to retain more commercial ownership of future medicines.
Genmab is scheduled to report third-quarter results on November 5, 2026.

Genmab, DK0010272202, Illustration mit AI erstellt.

Genmab's run of late-stage cancer-drug successes is reshaping the investment case ahead of its third-quarter results on November 5. In a report published on November 3, CNBC said the Danish biotech had delivered three successful Phase 3 outcomes in October.

Three trials change the outlook

Genmab's petosemtamab combined with Merck's Keytruda reduced the risk of death by 50% versus Keytruda alone in a Phase 3 study of patients with recurrent or metastatic head and neck cancer. The combination also improved response rates, with no new safety signals reported in the announcement cited by CNBC.

Earlier October results showed that Rina-S reduced the risk of disease progression or death by 71% and the risk of death by 57% versus chemotherapy in a Phase 3 ovarian-cancer study. Epkinly, developed with AbbVie, reduced the risk of disease progression or death by 51% when combined with standard chemotherapy in previously untreated diffuse large B-cell lymphoma.

Ownership brings greater potential

Genmab has historically benefited from royalties on medicines developed with partners, including Johnson & Johnson's DARZALEX and Novartis' Kesimpta. Chief Executive Jan van de Winkel told CNBC that the company is using this financial base to retain a larger share of revenue from medicines it develops and sells.

That strategy can increase Genmab's commercial opportunity if its pipeline reaches patients, but it also leaves the company with more responsibility for clinical development, regulatory approvals and sales. Petosemtamab and Rina-S are fully owned by Genmab, while the company shares the commercial economics of Epkinly with AbbVie.

Genmab's business and competitive position

Genmab A/S is a Copenhagen-based biopharmaceutical company focused on discovering and developing antibody therapies for cancer and other serious diseases. Its portfolio includes antibody medicines such as DARZALEX, teprotumumab, ofatumumab, amivantamab and tisotumab vedotin, alongside a broad clinical pipeline. The company competes in the specialist antibody and oncology market while using partnerships with larger pharmaceutical groups to expand development and commercialization.